What is MariTide?
MariTide (maridebart cafraglutide, formerly AMG 133) is Amgen's entry into the obesity drug market. It is a first-in-class antibody-peptide conjugate that combines two mechanisms in a single molecule: it activates the GLP-1 receptor (like Wegovy and Ozempic) while simultaneously blocking the GIP receptor.
This is a fundamentally different approach from tirzepatide (Zepbound/Mounjaro), which activates both GLP-1 and GIP receptors. MariTide bets that blocking GIP while activating GLP-1 produces better outcomes than dual activation.
The other major differentiator: MariTide is dosed once per month, compared to weekly injections for semaglutide and tirzepatide.
The mechanism: why block GIP instead of activating it?
This is the central scientific question around MariTide, and it is worth understanding because it determines whether this drug represents a genuine advance or a lateral move.
The GIP debate. GIP (glucose-dependent insulinotropic polypeptide) is a gut hormone with complex, sometimes contradictory roles. Tirzepatide's success proved that activating GIP alongside GLP-1 produces excellent weight loss and metabolic improvement. But GIP signaling also promotes fat storage in adipose tissue — GIP tells fat cells to take up and store fatty acids. This dual role creates a genuine scientific question: would you get better fat loss by blocking GIP instead of stimulating it?
Amgen's hypothesis. By blocking GIP receptors, MariTide may reduce fat storage signaling in adipose tissue while the GLP-1 agonist component suppresses appetite and slows gastric emptying. The theory is that you get the appetite suppression benefits of GLP-1 agonism plus enhanced fat mobilization from GIP blockade — a different path to the same goal.
The counterargument. GIP activation in the brain may contribute to satiety and improved insulin sensitivity in ways that GIP blockade misses. Tirzepatide's clinical results are hard to argue with, and some researchers believe that centrally mediated GIP agonism is doing important work that peripheral GIP blockade in fat tissue cannot replace.
The honest answer is that we do not know yet which approach is better. Phase 3 data will begin to settle this debate. Both mechanisms have plausible biological rationale.
How the antibody-peptide conjugate works
MariTide uses an antibody-peptide conjugate (APC) platform. In practical terms:
- A GLP-1-mimicking peptide (the active drug) is chemically attached to an anti-GIP antibody (the carrier and second mechanism).
- The antibody portion binds GIP receptors and blocks GIP signaling.
- The peptide portion activates GLP-1 receptors, providing the standard GLP-1 effects: appetite suppression, blood sugar control, slowed gastric emptying.
- The antibody carrier gives MariTide a very long half-life (estimated 3-4 weeks), enabling once-monthly dosing.
This is a genuinely novel drug design. Traditional GLP-1 receptor agonists are peptide-based and clear the body in days to a week. By conjugating the peptide to an antibody, Amgen extended the duration of action dramatically. The same design also means the GIP-blocking component is always present alongside the GLP-1 agonism — you cannot separate the two effects.
Phase 2 trial data
MariTide's Phase 2 data, presented in 2024, showed meaningful results:
Weight loss: Participants on the highest dose lost up to approximately 14.5% of body weight at 12 weeks. This was only 12 weeks of treatment — a short duration by GLP-1 trial standards. For context, semaglutide 2.4mg (Wegovy) produces roughly 6-8% weight loss at 12 weeks in comparable trials, reaching ~15% at 68 weeks. Tirzepatide produces roughly 7-10% at 12 weeks, reaching ~20-22% at 72 weeks.
Rate of loss. The 12-week rate of weight loss on MariTide was competitive with or faster than semaglutide and tirzepatide at comparable timepoints. Extrapolating from 12-week data is speculative, but if the trajectory held, MariTide could reach 20%+ total body weight loss over a full treatment course. This remains to be proven in Phase 3.
Dose-response. MariTide showed a clear dose-response relationship — higher doses produced more weight loss. Multiple dose levels were tested, and the safety profile was acceptable across the range.
Weight maintenance signal. Perhaps the most interesting finding: some participants who stopped MariTide appeared to maintain their weight loss better than is typical for GLP-1 discontinuation. The extended pharmacological effect (the drug stays active in the body for weeks after the last dose due to the antibody carrier) may provide a natural buffer against immediate regain. This is early, small-sample data, but if confirmed in Phase 3, it would be a meaningful clinical advantage.
How MariTide compares in the competitive landscape
vs. Tirzepatide (dual agonist). Tirzepatide activates both GLP-1 and GIP. MariTide activates GLP-1 and blocks GIP. Both produce significant weight loss. Tirzepatide has extensive Phase 3 data and FDA approval. MariTide is still in trials. The head-to-head comparison will be the most important data readout in obesity pharmacology over the next 2-3 years.
vs. Retatrutide (triple agonist). Eli Lilly's retatrutide activates GLP-1, GIP, and glucagon receptors. Phase 2 data showed up to 24% body weight loss at 48 weeks. If retatrutide's Phase 3 data holds up, it may set a new efficacy ceiling that MariTide would need to match. Retatrutide is also in Phase 3 trials with results expected in 2025-2026.
vs. Oral semaglutide (Rybelsus / high-dose oral). Novo Nordisk is developing high-dose oral semaglutide for obesity. This addresses the convenience question differently — no injection at all. MariTide's monthly injection competes on convenience against weekly injection but loses to a daily pill for patients who strongly prefer oral medications.
Amgen's strategy in the obesity market
Amgen is entering the obesity market as a large pharma company with deep manufacturing and regulatory expertise but no prior obesity franchise. Their strategy appears built around three pillars:
Differentiation through dosing. Monthly injection is a genuine convenience advantage that no current competitor offers. This alone could carve out market share among patients who find weekly injections burdensome.
Manufacturing scale. Amgen has extensive biologics manufacturing capacity. The antibody-peptide conjugate platform uses manufacturing processes similar to Amgen's existing monoclonal antibody portfolio. This could give MariTide a supply advantage if demand outstrips capacity — a problem that plagued semaglutide and tirzepatide launches.
Novel mechanism. The GIP-blocking approach, if validated, gives Amgen a differentiated position in a market that could otherwise become crowded with GLP-1/GIP dual agonist variations.
Expected pricing and access
Amgen has not announced pricing, but market dynamics suggest MariTide will likely price competitively with Wegovy (~$1,350/month list) and Zepbound (~$1,060/month list). Pricing significantly above competitors would be difficult to justify without clearly superior efficacy data. Pricing below could accelerate adoption but would depend on manufacturing costs for the antibody-peptide conjugate, which are likely higher than simple peptide production.
FDA timeline and Phase 3 design
Phase 3 (MARITIME program): Multiple Phase 3 trials are enrolling as of 2026, including studies against placebo, against existing treatments, and in specific populations (type 2 diabetes, cardiovascular risk reduction). The program is designed to support a broad obesity indication.
Optimistic timeline: Phase 3 data readout in late 2027, FDA submission in 2028, potential approval in late 2028 or 2029.
Realistic timeline: Approval in 2029-2030. Amgen is experienced with FDA but the novel mechanism (GIP blockade vs. agonism) may attract additional regulatory scrutiny, particularly around long-term cardiovascular safety.
Potential advantages for specific patients
MariTide may be particularly well-suited for patients who have difficulty with weekly injection adherence (monthly dosing reduces friction by 75%), patients who have tried GLP-1/GIP dual agonists and plateaued (the different mechanism could produce additional response), patients concerned about weight regain after stopping treatment (if the maintenance signal from Phase 2 holds), and patients with needle anxiety who want the fewest possible injections.
These are speculative advantages until Phase 3 data confirms them. Consult a prescriber about whether MariTide might eventually be appropriate for your situation.
What this means for the market
MariTide represents three things for patients watching the obesity drug space:
Competition. A credible third player (alongside Novo Nordisk and Eli Lilly) entering the obesity drug space should drive pricing competition over time. More competition is unambiguously good for patients.
Convenience. Monthly dosing is a genuine quality-of-life improvement for patients on long-term therapy.
Science. The GIP-blocking vs. GIP-activating debate will have real clinical data to resolve it. If MariTide performs comparably to tirzepatide, it validates an entirely new approach to obesity pharmacotherapy and opens the door to further innovation.
MariTide is not an option today, but it is worth watching. For the full landscape of drugs in development, see our GLP-1 pipeline tracker.